NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Ustekinumab市場分析(2021年∼2025年)

Investigation Report on China's Ustekinumab Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1006914
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Ustekinumab市場分析(2021年∼2025年) Investigation Report on China's Ustekinumab Market 2021-2025
出版日期: 2021年05月21日內容資訊: 英文 50 Pages
簡介

Ustekinumab,是Janssen Pharmaceuticals 所開發的單株抗體醫藥品,主要用於乾癬,克隆氏症,潰瘍性大腸炎的治療。Janssen Pharmaceuticals的Ustekinumab "TELARA" ,2017年11月中國首次承認,2019年正式商品化銷售。至2020年,中國市場,Janssen-Cilag International NV 成為唯一的Ustekinumab的製藥企業。

中國市場進入後,Ustekinumab的銷售量,從2019年的60萬人民幣,2020年增加到225萬人民幣,記錄了274%的年度成長率。

本報告提供中國的Ustekinumab市場相關調查,產品概要,新型冠狀病毒感染疾病(COVID-19)的影響,中國整體及各地區的銷售趨勢,製藥企業的市場佔有率,銷售額及銷售額數,價格趨勢,市場預測,市場成長要素,市場機會,課題等資料彙整。

目錄

第1章 Ustekinumab概要

  • Ustekinumab的適應症
  • 中國的Ustekinumab的開發
  • 中國的Ustekinumab的政府核准
  • 新型冠狀病毒感染疾病(COVID-19)對銷售的影響

第2章 中國的Ustekinumab的銷售趨勢(2019年∼2020年)

  • Ustekinumab的銷售額
    • 銷售額:全體
    • 銷售額:各地區
  • Ustekinumab的銷售額數
    • 銷售額數:全體
    • 銷售額數:各地區
  • Ustekinumab的銷售趨勢:各劑型
    • 注射劑
    • 其他劑型

第3章 中國的主要Ustekinumab製造企業(2019年∼2020年)

  • 主要企業的市場佔有率
    • 銷售額
    • 銷售額數
  • Janssen-Cilag International NV(BE)
    • 企業簡介
    • Stelara(STELARA)的中國國內的銷售額

第4章 中國的Ustekinumab的價格(2020年∼2021年)

  • Janssen-Cilag International NV(BE)(Stelara/STELARA)

第5章 中國的Ustekinumab市場預測(2021年∼2025年)

  • 市場發展的影響要素
    • 新型冠狀病毒感染疾病(COVID-19)的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105482

Ustekinumab is a monoclonal antibody medication developed by Janssen Pharmaceuticals. It is mainly used to treat psoriasis, Crohn's disease, and ulcerative colitis. Janssen's Ustekinumab, STELARA was approved for its first indication in China in November 2017 and was officially commercialized and sold in 2019. By 2020, Janssen-Cilag International NV (BE) is the only manufacturer in the Chinese Ustekinumab market.

According to CRI's market research, after Ustekinumab entered the Chinese market, the sales increased from CNY0.6 million in 2019 to CNY 2.25 million in 2020. The annual growth rate is 274%

CRI analyzes that the sales of Ustekinumab will continue to increase in the next five years due to market expansion. After Ustekinumab was approved for its first indication in China in 2017, its second indication was approved in March 2020, which is used to treat moderate to severe active Crohn's disease. With the approval of the new indication, sales will increase accordingly. Besides, Ustekinumab had four approved indications globally, which means the number of approved indications has the potential to expand in China, so the sales will keep increasing. On the other hand, the relatively high price for Ustekinumab results in suboptimal sales in China. Since Ustekinumab has only been in the Chinese market for a short period, Janssen is not enthusiastic about the national medical insurance negotiation. However, with the emergence of domestic biosimilar drugs in the future, the price for Ustekinumab is expected to decrease and the market will be further expanded.

Topics Covered:

  • The impact of COVID-19 on China's Ustekinumab market
  • Sales value and volume of China's Ustekinumab 2016-2020
  • Competitive landscape of China's Ustekinumab market
  • Prices of Ustekinumab in China
  • Prices of Ustekinumab in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Ustekinumab market
  • Prospect of China's Ustekinumab market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Ustekinumab

  • 1.1 Indications for Ustekinumab
  • 1.2 Development of Ustekinumab in China
  • 1.3 Governmental Approval of Ustekinumab in China
  • 1.4 The Impact of COVID-19 on Ustekinumab sales in China

2 Sales of Ustekinumab in China, 2019-2020

  • 2.1 Sales Value of Ustekinumab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Ustekinumab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Ustekinumab by Dosage Form in China, 2019-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Ustekinumab Manufacturers in China, 2019-2020

  • 3.1 Analysis of Market Share of Major Ustekinumab Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Janssen-Cilag International NV (BE)
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of STELARA (Janssen's Ustekinumab) in China

4 Prices of Ustekinumab for Different Manufacturers in China, 2020-2021

  • 4.1 Janssen-Cilag International NV (BE) (STELARA)

5 Prospect of Chinese Ustekinumab drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Ustekinumab Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Ustekinumab Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Ustekinumab Injection Registration in China
  • Chart Sales Value of Ustekinumab Injection over the World
  • Chart Sales Value of Ustekinumab Injection in China, 2019-2020
  • Chart Sales Value of Ustekinumab Injection in China by Regions, 2019-2020
  • Chart Sales Volume of Ustekinumab Injection in China, 2019-2020
  • Chart Sales Volume of Ustekinumab Injection in China by Regions, 2019-2020
  • Chart Market Share by Sales Value of Top Ustekinumab Manufacturers in China, 2019-2020
  • Chart Sales Value and Volume of STELARA in China, 2019-2020
  • Chart Referential Prices of STELARA in China, 2020-2021
  • Chart Forecast on Sales Value of Ustekinumab in China, 2021-2025
  • Chart Forecast on Sales Volume of Ustekinumab in China, 2021-2025